Kindred Bio Completes Follow-on Public Offering

TroyGould members Sandy Hillsberg and Dale Short and associate Dietrick Miller handled the recently completed $62.1 million follow-on public offering by Kindred Biosciences, Inc. TroyGould also handled Kindred’s $60.375 million initial public offering in December 2013. Leerink Partners LLC acted as lead book-running manager, with BMO Capital Markets Group, Inc. and Guggenheim Securities, LLC acting as active joint book-running managers for the offering.

Kindred Biosciences (NASDAQ: KIN) is a development stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy.